The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 2, 2011, Pages 573-576

  Ohta, Chikako ^a   Yasui Furukori, Norio ^a   Furukori, Hanako ^a   Tsuchimine, Shoko ^a   Saito, Manabu ^a   Nakagami, Taku ^a   Yoshizawa, Kaori ^a   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Gender; Prolactin; Risperidone; Smoking status

Indexed keywords

ALPRAZOLAM; BIPERIDEN; DIAZEPAM; FLUNITRAZEPAM; LORAZEPAM; PALIPERIDONE; PROLACTIN; RISPERIDONE; SENNOSIDE; TRIHEXYPHENIDYL;

ADULT; AGE; ARTICLE; BEDTIME DOSAGE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MULTIPLE REGRESSION; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; SEX DIFFERENCE; SMOKING; TREATMENT DURATION;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; MIDDLE AGED; PROLACTIN; RISPERIDONE; SCHIZOPHRENIA; SEX CHARACTERISTICS; SMOKING; YOUNG ADULT;

EID: 79952899638     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.12.025     Document Type: Article

References (32)

1. Callaghan J.T., Bergstrom R.F., Ptak L.R., Beasley C.M. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999, 37(3):177-193. Sep.
2. Caracci G., Ananthamoorthy R. Prolactin levels in premenopausal women treated with risperidone compared with those of women treated with typical neuroleptics. J Clin Psychopharmacol 1999, 19:194-196.
3. Carrillo J.A., Herráiz A.G., Ramos S.I., Gervasini G., Vizcaíno S., Benítez J. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 2003, 23(2):119-127. Apr.
4. Corona G., Mannucci E., Petrone L., Ricca V., Mansani R., Cilotti A., et al. Psychobiological correlates of smoking in patients with erectile dysfunction. Int J Impot Res 2005, 17(6):527-534. Nov-Dec.
5. David S.R., Taylor C.C., Kinon B.J., Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000, 22:1085-1096.
6. Dickson R.A., Dalby J.T., Williams R., Edwards A.L. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. Am J Psychiatry 1995, 152:1102-1103.
7. Fang J., Bourin M., Baker G.B. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 1999, 359(2):147-151. Feb.
8. Kapur S., Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001, 158:360-369.
9. Kim Y.K., Kim L., Lee M.S. Risperidone and associated amenorrhea: a report of 5 cases. J Clin Psychiatry 1999, 60:315-317.
10. Kirschbaum C., Scherer G., Strasburger C.J. Pituitary and adrenal hormone responses to pharmacological, physical, and psychological stimulation in habitual smokers and nonsmokers. Clin Investig 1994, 72(10):804-810. Oct.
11. Kleinberg D.L., Davis J.M., de Coster R., Van Baelen B., Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999, 19:57-61.
12. Lavalaye J., Linszen D.H., Booij J., Reneman L., Gersons B.P., van Royen E.A. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia. Psychiatry Res 1999, 92:33-44.
13. Mansvelder H.D., Keath J.R., McGehee D.S. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 2002, 33(6):905-919. Mar 14.
14. Meaney A.M., Smith S., Howes O.D., O'Brien M., Murray R.M., O'Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004, 184:503-508. Jun.
15. Mendelson J.H., Sholar M.B., Mutschler N.H., Jaszyna-Gasior M., Goletiani N.V., Siegel A.J., et al. Effects of intravenous cocaine and cigarette smoking on luteinizing hormone, testosterone, and prolactin in men. J Pharmacol Exp Ther 2003, 307(1):339-348. Oct.
16. Mihara K., Kondo T., Yasui-Furukori N., Suzuki A., Ishida M., Ono S., et al. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther Drug Monit 2003, 25:287-293.
17. Petty R.G. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 1999, 35:S67-S73.
18. Popli A., Gupta S., Rangwani S.R. Risperidone-induced galactorrhea associated with a prolactin elevation. Ann Clin Psychiatry 1998, 10:31-33.
19. Rubin R.T. Prolactin and schizophrenia. Psychopharmacology: The third generation of progress 1987, 803-808. Raven Press, New York. H.Y. Meltzer (Ed.).
20. Sagud M., Mihaljević-Peles A., Mück-Seler D., Pivac N., Vuksan-Cusa B., Brataljenović T., et al. Smoking and schizophrenia. Psychiatr Danub 2009, 21(3):371-375. Sep.
21. Schotte A., Bonaventure P., Janssen P.F.M., Leysen J.E. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotic hitherto used. Jpn J Pharmacol 1995, 69:399-412.
22. Shiwach R.S., Carmody T.J. Prolactogenic effects of risperidone in male patients - a preliminary study. Acta Psychiatr Scand 1998, 98(1):81-83. Jul.
23. Trummer H., Habermann H., Haas J., Pummer K. The impact of cigarette smoking on human semen parameters and hormones. Hum Reprod 2002, 17(6):1554-1559. Jun.
24. Walter-Sack I., Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 1996, 31(1):47-64. Jul.
25. Xue Y., Morris M., Ni L., Guthrie S.K., Zubieta J.K., Gonzalez K., et al. Venous plasma nicotine correlates of hormonal effects of tobacco smoking. Pharmacol Biochem Behav 2010, 95(2):209-215. Apr.
26. Yasui N., Kondo T., Otani K., Ishida M., Mihara K., Suzuki A., et al. Prolactin response to bromperidol treatment in schizophrenic patients. Pharmacol Toxicol 1998, 82:153-156.
27. Yasui-Furukori N., Kondo T., Suzuki A., Mihara K., Tokinaga N., Inoue Y., et al. Effect of the CYP2D6 genotype on prolactin concentration in schizophrenic patients treated with haloperidol. Schizophr Res 2001, 52:139-142.
28. Yasui-Furukori N., Kondo T., Suzuki A., Mihara K., Kaneko S. Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia. Psychopharmacology (Berl) 2002, 162:63-66.
29. Yasui-Furukori N., Mihara K., Kondo T., Kubota T., Iga T., Takarada Y., et al. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. J Clin Pharmacol 2003, 43:122-127.
30. Yasui-Furukori N., Mihara K., Takahata T., Suzuki A., Nakagami T., De Vries R., et al. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br J Clin Pharmacol 2004, 57:569-575.
31. Yasui-Furukori N., Tsuchimine S., Saito M., Nakagami T., Sato Y., Kaneko S. Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31(6):1230-1234. Aug 15.
32. Yasui-Furukori N., Saito M., Tsuchimine S., Nakagami T., Sato Y., Sugawara N., et al. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(6):1491-1495. Aug 1.